Analysts expect TG Therapeutics Inc (NASDAQ:TGTX) to announce sales of $40,000.00 for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for TG Therapeutics’ earnings. TG Therapeutics also posted sales of $40,000.00 during the same quarter last year. The firm is scheduled to issue its next earnings results on Friday, November 8th.
On average, analysts expect that TG Therapeutics will report full year sales of $170,000.00 for the current financial year, with estimates ranging from $150,000.00 to $200,000.00. For the next year, analysts expect that the company will report sales of $18.82 million, with estimates ranging from $150,000.00 to $52.32 million. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for TG Therapeutics.
TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Friday, August 9th. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.43) by $0.01. The firm had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.04 million. TG Therapeutics had a negative net margin of 99,488.13% and a negative return on equity of 496.99%.
In other TG Therapeutics news, CFO Sean A. Power sold 17,654 shares of the business’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $8.47, for a total transaction of $149,529.38. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Michael S. Weiss bought 50,000 shares of the stock in a transaction on Wednesday, June 26th. The shares were acquired at an average price of $7.04 per share, with a total value of $352,000.00. The disclosure for this purchase can be found here. 14.20% of the stock is currently owned by insiders.
A number of hedge funds have recently added to or reduced their stakes in TGTX. BlackRock Inc. boosted its holdings in shares of TG Therapeutics by 19.5% during the second quarter. BlackRock Inc. now owns 5,304,463 shares of the biopharmaceutical company’s stock valued at $45,883,000 after acquiring an additional 866,572 shares during the period. Vanguard Group Inc. boosted its holdings in shares of TG Therapeutics by 19.7% during the second quarter. Vanguard Group Inc. now owns 4,041,122 shares of the biopharmaceutical company’s stock valued at $34,955,000 after acquiring an additional 665,380 shares during the period. Sofinnova Investments Inc. boosted its holdings in shares of TG Therapeutics by 258.5% during the second quarter. Sofinnova Investments Inc. now owns 1,261,384 shares of the biopharmaceutical company’s stock valued at $10,911,000 after acquiring an additional 909,573 shares during the period. Camber Capital Management LP acquired a new position in shares of TG Therapeutics during the second quarter valued at $8,650,000. Finally, Artal Group S.A. boosted its holdings in shares of TG Therapeutics by 12.5% during the second quarter. Artal Group S.A. now owns 900,000 shares of the biopharmaceutical company’s stock valued at $7,785,000 after acquiring an additional 100,000 shares during the period. Hedge funds and other institutional investors own 52.96% of the company’s stock.
Shares of NASDAQ TGTX traded down $0.32 during midday trading on Monday, reaching $6.47. 991,308 shares of the stock were exchanged, compared to its average volume of 990,117. TG Therapeutics has a 52-week low of $3.32 and a 52-week high of $11.15. The company has a debt-to-equity ratio of 2.77, a quick ratio of 1.69 and a current ratio of 1.69. The stock has a 50 day moving average price of $6.71 and a 200-day moving average price of $7.28.
About TG Therapeutics
TG Therapeutics, Inc, a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing.
Further Reading: What is a good rate of return for a mutual fund?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.